MA52712A - Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine - Google Patents

Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine

Info

Publication number
MA52712A
MA52712A MA052712A MA52712A MA52712A MA 52712 A MA52712 A MA 52712A MA 052712 A MA052712 A MA 052712A MA 52712 A MA52712 A MA 52712A MA 52712 A MA52712 A MA 52712A
Authority
MA
Morocco
Prior art keywords
dipeptidic
dpr
repetitions
poly
directed against
Prior art date
Application number
MA052712A
Other languages
English (en)
Inventor
Joseph Walter Arndt
Isin Dalkilic-Liddle
Jan Grimm
Fabio Montrasio
Mia Marie Rushe
Original Assignee
Biogen Ma Inc
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Neurimmune Ag filed Critical Biogen Ma Inc
Publication of MA52712A publication Critical patent/MA52712A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
MA052712A 2018-04-27 2019-04-25 Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine MA52712A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18169888 2018-04-27
US201862772809P 2018-11-29 2018-11-29

Publications (1)

Publication Number Publication Date
MA52712A true MA52712A (fr) 2021-03-31

Family

ID=68293585

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052712A MA52712A (fr) 2018-04-27 2019-04-25 Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine

Country Status (14)

Country Link
US (1) US20220153874A1 (fr)
EP (1) EP3797114A4 (fr)
JP (1) JP2021521896A (fr)
KR (1) KR20210018807A (fr)
CN (1) CN112638932A (fr)
AU (1) AU2019261450B2 (fr)
BR (1) BR112020021855A2 (fr)
CA (1) CA3097872A1 (fr)
CO (1) CO2020014663A2 (fr)
MA (1) MA52712A (fr)
MX (1) MX2020011312A (fr)
TW (1) TWI842708B (fr)
UY (1) UY38203A (fr)
WO (1) WO2019210054A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113365640A (zh) 2018-12-06 2021-09-07 比奥根Ma公司 引导肌萎缩侧索硬化症的治疗性干预的神经丝蛋白
EP4427049A1 (fr) * 2021-11-01 2024-09-11 University Of Florida Research Foundation, Incorporated Protéines de poly-ga dans la maladie d'alzheimer
WO2023099788A1 (fr) 2021-12-03 2023-06-08 Neurimmune Ag Nouveau dosage de puissance pour des médicaments à base d'anticorps et moyens utiles associés
WO2023244542A1 (fr) * 2022-06-13 2023-12-21 Yeefan Med Inc Procédés de détection de précipités de b-isox ou de protéines capturées en tant que biomarqueurs de biofluide
CN115819513B (zh) * 2022-07-25 2023-10-17 东北农业大学 一种月桂酸修饰抗酶解肽及其制备方法和应用
CN115819543B (zh) * 2022-11-29 2023-07-21 华南师范大学 转录因子Tbx20启动子区G4调控元件在害虫防治中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014114303A1 (fr) * 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Protéines à répétitions de dipeptides comme cible thérapeutique dans des maladies neurodégénératives avec expansion de répétitions hexanucléotidiques
US9448232B2 (en) * 2013-01-24 2016-09-20 Mayo Foundation For Medical Education And Research Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
SG11201701925XA (en) * 2014-09-30 2017-04-27 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
WO2017136313A1 (fr) * 2016-02-01 2017-08-10 The Board Of Regents Of The University Of Texas System Mutations qui entraînent une autoréactivité des anticorps vh4
US10870709B2 (en) * 2016-07-22 2020-12-22 New York University Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides

Also Published As

Publication number Publication date
AU2019261450A1 (en) 2020-11-05
BR112020021855A2 (pt) 2021-02-23
UY38203A (es) 2019-11-29
CN112638932A (zh) 2021-04-09
MX2020011312A (es) 2021-03-26
CO2020014663A2 (es) 2021-03-08
WO2019210054A1 (fr) 2019-10-31
TW202014438A (zh) 2020-04-16
TWI842708B (zh) 2024-05-21
EP3797114A4 (fr) 2022-05-11
KR20210018807A (ko) 2021-02-18
US20220153874A1 (en) 2022-05-19
EP3797114A1 (fr) 2021-03-31
JP2021521896A (ja) 2021-08-30
CA3097872A1 (fr) 2019-10-31
AU2019261450B2 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
MA52712A (fr) Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
JP1721955S (ja) ブローチ
MA47468A (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
JP1714574S (ja) ブローチ
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
DK3737399T3 (da) Atf5-peptidvarianter og anvendelser deraf
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
ZA202107587B (en) Aqueous pharmaceutical compositions of an anti-il17a antibody and use thereof
JP1721983S (ja) ブローチ
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA53466A (fr) Formulation stable d'anticorps anti-osmr
MA49273A (fr) Anticorps anti-tmeff1 et conjugués anticorps-médicament
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
JP1721969S (ja) ブローチ
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
MA52021A (fr) Anticorps anti-lif et leurs formes galéniques
DK3710485T3 (da) Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
MA52485A (fr) Combinaisons de variants d'anticorps et utilisations associées
MA55761A (fr) Formulations et anticorps anti-cd38
DK3768265T3 (da) Ny centralt aktiv ghrelin-agonist og medicinske anvendelser deraf
MA49627A (fr) Associations pharmaceutiques comprenant un anticorps anti-bst-1 et un analogue de cytidine